MESO - Mesoblast Limited
NASDAQ
->
Healthcare
->
Biotechnology
Melbourne,
Australia
Type: Equity
MESO price evolution
MESO
| (in millions $) | 31 Jan 2024 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $77.14 | $70.92 | $48.4 | $67.21 |
| Short term investments | ||||
| Net receivables | $4 | $7 | $8.39 | $5.12 |
| Inventory | ||||
| Total current assets | $85.15 | $81.66 | $61.37 | $78.13 |
| Long term investments | ||||
| Property, plant & equipment | $5.5 | $6.49 | $7.13 | $8.15 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $670.28 | $669.41 | $650.44 | $668.06 |
| Current liabilities | ||||
| Accounts payable | $10.76 | $20.14 | $20.97 | $22.99 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $31.37 | $41.98 | $53.92 | $54.58 |
| Long term debt | $110.61 | $106.48 | $103.69 | $101.98 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $161.55 | $167.58 | $168.27 | $168.06 |
| Shareholders' equity | ||||
| Retained earnings | -$736.91 | -$706.47 | -$685.62 | -$707.71 |
| Other shareholder equity | -$39.11 | -$0.54 | -$39.45 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2023 | 30 Jul 2022 | 29 Jul 2021 | 29 Jun 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $70.92 | $60.03 | $136.88 | $129.33 |
| Short term investments | ||||
| Net receivables | $7 | $4.4 | $4.84 | $0.85 |
| Inventory | ||||
| Total current assets | $81.66 | $69.84 | $148.23 | $136.55 |
| Long term investments | $1.76 | $2.08 | $1.87 | |
| Property, plant & equipment | $6.49 | $9.96 | $3.02 | $10.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $596.49 | $597.05 | ||
| Total investments | ||||
| Total assets | $669.41 | $662.14 | $744.72 | $733.6 |
| Current liabilities | ||||
| Accounts payable | $20.14 | $23.08 | $19.6 | $24.97 |
| Deferred revenue | ||||
| Short long term debt | $5.02 | $53.2 | $32.45 | |
| Total current liabilities | $41.98 | $51.37 | $94.27 | $90.14 |
| Long term debt | $106.48 | $98.7 | $41.05 | $57.02 |
| Total noncurrent liabilities | $69.05 | $94.13 | ||
| Total debt | ||||
| Total liabilities | $167.58 | $165.1 | $163.32 | $184.28 |
| Shareholders' equity | ||||
| Retained earnings | -$706.47 | -$628.02 | -$647.57 | -$548.76 |
| Other shareholder equity | -$0.54 | -$0.54 | $65.81 | $46.63 |
| Total shareholder equity | $497.04 | $581.4 | $549.33 | |
| (in millions $) | 31 Jan 2024 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.39 | $2.14 | $1.94 | $2.13 |
| Cost of revenue | ||||
| Gross Profit | -$3.36 | -$6.59 | -$4.31 | -$5.76 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $20.03 | $11.5 | $9.56 | $12.86 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.1 | -$0.04 | -$0.05 | -$0.07 |
| Interest expense | -$9.13 | -$4.51 | -$4.77 | -$4.65 |
| Net income | ||||
| Net income | -$32.54 | -$21.92 | -$18.6 | -$24.49 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2023 | 30 Jul 2022 | 29 Jul 2021 | 29 Jun 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.5 | $10.21 | $7.46 | $32.16 |
| Cost of revenue | $25.31 | |||
| Gross Profit | -$20.23 | -$20.54 | -$25.26 | $6.85 |
| Operating activities | ||||
| Research & development | $56.19 | |||
| Selling, general & administrative | $25.61 | |||
| Total operating expenses | $42.49 | $53.22 | $64.37 | $107.81 |
| Operating income | -$88.92 | -$75.65 | ||
| Income from continuing operations | ||||
| EBIT | -$75.65 | |||
| Income tax expense | -$0.21 | -$0.24 | -$0.82 | -$9.41 |
| Interest expense | -$18.78 | -$17.44 | $10.71 | -$14.72 |
| Net income | ||||
| Net income | -$81.89 | -$91.35 | -$98.81 | -$77.94 |
| Income (for common shares) | -$77.94 | |||
| (in millions $) | 31 Jan 2024 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.09 | -$0.19 | -$0.21 | -$0.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $31.6 | $74.5 | $35.74 | $38.29 |
| Effect of exchange rate | $1.3 | -$0.17 | -$0.19 | -$0.14 |
| Change in cash and equivalents | $6.24 | $10.87 | -$11.65 | $7.17 |
| (in millions $) | 30 Jul 2023 | 30 Jul 2022 | 29 Jul 2021 | 29 Jun 2020 |
|---|---|---|---|---|
| Net income | -$98.81 | -$77.94 | ||
| Operating activities | ||||
| Depreciation | $3.67 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$106.68 | -$56.37 | ||
| Investing activities | ||||
| Capital expenditures | -$2.1 | |||
| Investments | ||||
| Total cash flows from investing | -$0.19 | -$0.23 | -$1.65 | -$3.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$1.63 | |||
| Total cash flows from financing | $74.5 | -$9.87 | $114.47 | $137.04 |
| Effect of exchange rate | -$0.17 | -$0.55 | $1.42 | $1.5 |
| Change in cash and equivalents | $10.87 | -$76.43 | $7.55 | $78.9 |
News
Fundamentals
| Market cap | $743.82M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 120.95M |
| Revenue | $9.60M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$97.54M |
| Revenue Q/Q | 125.42% |
| Revenue Y/Y | 18.20% |
| P/E ratio | -7.63 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 77.48 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.64 |
| EPS | -$0.81 |
|---|---|
| ROA | -14.68% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.71 |
| Quick ratio | N/A |